A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TCC1727 Tablets in Patients with Advanced Solid Tumor.

Beijing Tide Pharmaceutical Co., Ltd1 个研究点分布在 1 个国家目标入组 56 人开始时间: 2023年8月7日最近更新: 2025年3月21日

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方: Beijing Tide Pharmaceutical Co., Ltd
入组人数: 56
试验地点: 1
主要终点: Phase I: To determine dose-limiting toxicity (DLT) at each dose level and identify MTD and RP2D.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.

详细描述

The study will be divided into two stages: the first stage is a phase I dose finding study in patients with advanced solid tumors; the second stage is a phase II cohort expansion study.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 70 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female subjects who have provided voluntary informed consent for participation in the study and to follow the protocol requirements
•Male or female subjects 18-70 years of age
•Subjects with histologically or cytologically confirmed malignant advanced solid tumors who have progressed on (or have not been able to tolerate) standard therapy or for whom no suitable effective standard therapy exists
•For Phase I, all tumor types will be enrolled
•For Phase II, Patients with DDR defects detection at central laboratory will be enrolled
•Subject with at least one measurable lesion according to RECIST criteria (version 1.1) for solid tumors will be allowed to include in phase II (if there is no measurable lesion but there are assessable lesions then the subject will be allowed to be included after the judgment of the investigator in phase I only)
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
•Subjects with life expectancy of ≥12 weeks
•Subjects 12-lead ECG evaluation of QT level using Fridericia formula (QTcF) < 450 mse
•Subjects must have the following laboratory values:
•Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;
•Platelet count (PLT) ≥ 100 × 109/L;
•Hemoglobin (HB) ≥ 9.0 g/L;
•No blood transfusion or hematopoietic stimulating factor treatment within 14 days;
•Bilirubin total ≤ 1.5 times the upper limit of normal (ULN);
•Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (In case of liver metastasis, ALT and AST ≤ 5 × ULN);
•24-hour or calculated creatinine clearance (CrCl) ≥ 60 mL/min (according to Cockcroft-Gault formula)*, or the 24-hour creatinine clearance measured in urine is ≥ 50 mL/min, the patient will still be selected. *For CrCl value, the eligibility should be determined using the Cockcroft-Gault formula:
•Male CrCl (mL/min) = body weight (kg) × (140 - age)/[72 × serum creatinine (mg/dL)]
•Female CrCl (mL/min) = male CrCl × 0.85
•International normalized ratio (INR) ≤ 1.5 × ULN, Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;
•Women of childbearing potential agreed to use effective contraceptives during the study treatment period and within 3 months after the end of the study treatment period.

排除标准

•Subjects will be excluded from the study based on the following criteria:
•Imaging examination suggests intracranial metastasis, which requires local treatment (in case of asymptomatic or symptomatic brain metastasis requiring no local treatment based on the investigator's judgement, the subject can still be included), or currently taking steroid hormone prior to inclusion, such as >10 mg prednisone (or equivalent) for intracerebral edema from brain metastases; subjects with meningeal carcinomatosis will be excluded regardless of their clinical stability
•History of previously received major surgery or surgical therapy for any cause within 4 weeks of the first dose; radiotherapy, chemotherapy, other clinical trial drugs or other anti-tumor treatment, within 5 half-lives or 3 weeks (whichever is shorter), prior administering the first dose of study drug on Day 1
•History of previous treatment with ATR inhibitors or other DDR related inhibitors (except poly ADP ribose polymerase enzyme (PARP) inhibitors)
•Subjects with a history of another primary malignancy other than:
•carcinomas in situ, (e.g., breast, cervix, and prostate)
•Locally excised non-melanoma skin cancer
•No evidence of disease from another primary cancer for two or more years and has not taken any anti-cancer treatment in two years. Exceptions are gonadotropin-releasing hormone (GnRH) therapy for prostate cancer and hormonal maintenance therapy for breast cancer.
•Previously received treatment with strong CYP3A4, CYP2C8 and P-gp inhibitors or strong CYP3A4, CYP2C8 and P-gp inducers within 14 days prior to the first medication
•Patients with AE due to previous anti-tumor treatment that has not recovered to ≤ CTCAE grade 1 (except for alopecia, pigmentation and lymphopenia)
•Patients who are unable to swallow the tablets normally, or have abnormal gastrointestinal function that may affect the drug absorption, such as malabsorption syndrome or major resection of the stomach or bowels based on the judgment of the investigator
•Subjects with any severe and/or uncontrolled disease, including:
•Poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg)
•Myocardial infarction, arrhythmia (CTCAE grade 2 and above, also including ≥ Class II congestive heart failure (CHF) (New York Heart Association (NYHA) classification) (refer to Appendix-A)
•Active infection or fever of unknown origin ≥ 38.5℃ within 7 days prior to the first medication
•Active viral hepatitis; positive hepatitis B surface antigen and/or hepatitis B core antibody and measured HBV DNA value ≥ 500 IU/ml; positive HCV antibody and measured HCV titer exceeding the upper limit of normal;
•Positive Treponema pallidum antibody;
•History of immunodeficiency, including positive HIV antibody or other acquired or congenital immunodeficiency diseases, or history of organ transplant;
•Poor control of diabetes (fasting blood glucose (FBG) > 10 mmol/L);
•Liver disease such as decompensated liver disease
•Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion as per the investigator opinion
•Patients with clinically significant hemorrhage symptoms or bleeding tendency within 3 months prior to the first study medication
•Known hypersensitivity or contraindication to any drug or any of the components of investigational product
•Any other clinically significant acute or chronic medical or psychiatric or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results